Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
In8bio Inc (INAB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: INAB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $107.7
1 Year Target Price $107.7
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -65.81% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.34M USD | Price to earnings Ratio - | 1Y Target Price 107.7 |
Price to earnings Ratio - | 1Y Target Price 107.7 | ||
Volume (30-day avg) 4 | Beta 0.18 | 52 Weeks Range 2.06 - 27.30 | Updated Date 06/30/2025 |
52 Weeks Range 2.06 - 27.30 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -13.2 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -73.25% | Return on Equity (TTM) -174.67% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -245340 | Price to Sales(TTM) - |
Enterprise Value -245340 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.15 | Shares Outstanding 3444230 | Shares Floating 2577285 |
Shares Outstanding 3444230 | Shares Floating 2577285 | ||
Percent Insiders 4.2 | Percent Institutions 20.98 |
Analyst Ratings
Rating 2 | Target Price 107.7 | Buy 2 | Strong Buy 2 |
Buy 2 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
In8bio Inc
Company Overview
History and Background
In8bio Inc. is a clinical-stage biopharmaceutical company focused on developing innovative gamma-delta T cell therapies for cancer. Founded in 2016, it has advanced multiple programs into clinical trials.
Core Business Areas
- DRT (Dose-Responsive Therapy): Developing autologous and allogeneic gamma-delta T cell therapies to treat solid tumors.
- DeltEx: Engineering gamma-delta T cells for enhanced tumor targeting and cytotoxic activity.
Leadership and Structure
The leadership team includes Trishna Goswami, CEO, and the organizational structure consists of research, clinical development, and manufacturing departments.
Top Products and Market Share
Key Offerings
- INB-400 (Dose-Responsive Therapy): An autologous DRT product candidate in a Phase 2 trial for newly diagnosed glioblastoma (GBM). Market share is not applicable at this stage as the product is still in development. Competitors include companies developing other GBM therapies like Merck (Temodar) and Novocure (Optune).
- INB-200 (Dose-Responsive Therapy): An autologous DRT product candidate in a Phase 1 trial for hematologic malignancies. Market share is not applicable at this stage. Competitors include companies developing CAR-T cell therapies like Gilead (Yescarta) and Novartis (Kymriah).
- INB-100 (DeltEx Platform): Allogeneic approach targeting solid tumor types. Market share is not applicable at this stage. Competitors include companies developing other allogeneic cell therapies like Allogene Therapeutics and Cellectis.
Market Dynamics
Industry Overview
The cell therapy market is rapidly growing, driven by advancements in immunotherapy and gene editing. It's characterized by high competition and significant investment.
Positioning
In8bio is positioned as a leader in gamma-delta T cell therapy development, focusing on solid tumors and hematologic malignancies with differentiated technology.
Total Addressable Market (TAM)
The total addressable market for cancer therapies is substantial, estimated in the hundreds of billions of dollars. In8bio is targeting specific segments within this broader market. The precise value specific to their approach is still developing and varies based on trial outcomes.
Upturn SWOT Analysis
Strengths
- Novel gamma-delta T cell platform
- Clinical-stage pipeline
- Strong scientific leadership
- Focus on solid tumors, an area of high unmet need
Weaknesses
- Limited financial resources compared to larger competitors
- Reliance on clinical trial success
- Relatively small market capitalization
- Technology risks associated with novel therapies
Opportunities
- Positive clinical trial results driving partnerships and funding
- Expansion into new indications
- Advancements in manufacturing processes
- Strategic collaborations with larger pharmaceutical companies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other immunotherapy approaches
- Market access and reimbursement challenges
Competitors and Market Share
Key Competitors
- GILD
- NVS
- ALLO
- CRIS
Competitive Landscape
In8biou2019s key advantage lies in its gamma-delta T cell technology. The main disadvantage is its smaller size and resources compared to competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth primarily reflects R&D progress and pipeline advancement.
Future Projections: Future projections are highly dependent on clinical trial outcomes and regulatory approvals. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing clinical trials for INB-400 and INB-200, expanding the DeltEx platform, and strengthening partnerships.
Summary
In8bio is a clinical-stage company with a promising gamma-delta T cell platform, but it's high risk due to its reliance on clinical trial success. The company's focus on solid tumors provides a significant opportunity. However, it faces competition from larger, well-established players and also requires substantial funding to reach commercialization. The company must manage its cash burn carefully and look out for competitor advancements.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About In8bio Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2021-07-30 | Co-Founder, President, CEO & Director Mr. Tai-Wei Ho | ||
Sector Healthcare | Industry Biotechnology | Full time employees 18 | Website https://in8bio.com |
Full time employees 18 | Website https://in8bio.com | ||
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its products include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; and INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is based in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.